.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Argus Health
US Department of Justice
AstraZeneca
Fish and Richardson
Boehringer Ingelheim
McKinsey
Medtronic
Cipla
UBS

Generated: November 19, 2017

DrugPatentWatch Database Preview

Endo Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for ENDO PHARM, and what generic alternatives to ENDO PHARM drugs are available?

ENDO PHARM has twenty-four approved drugs.

There are twenty-seven US patents protecting ENDO PHARM drugs on ENDO PHARM drugs in the past three years.

There are four hundred and seventy-three patent family members on ENDO PHARM drugs in forty-five countries and seven supplementary protection certificates in four countries.

Summary for Endo Pharm

International Patents:473
US Patents:27
Tradenames:20
Ingredients:17
NDAs:24
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Pharms
OPANA ER
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL201655-002Dec 9, 2011DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Endo Pharms
FORTESTA
testosterone
GEL, METERED;TRANSDERMAL021463-001Dec 29, 2010ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Endo Pharms
OPANA ER
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL201655-007Dec 9, 2011DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Endo Pharms
MOBAN
molindone hydrochloride
TABLET;ORAL017111-007Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Endo Pharms Inc
NASCOBAL
cyanocobalamin
SPRAY, METERED;NASAL021642-001Jan 31, 2005RXYesYes► Subscribe► Subscribe ► Subscribe
Endo Pharms Inc
AVEED
testosterone undecanoate
INJECTABLE;INTRAMUSCULAR022219-001Mar 5, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Endo Pharms
OPANA ER
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL201655-005Dec 9, 2011DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Endo Pharms
FORTESTA
testosterone
GEL, METERED;TRANSDERMAL021463-001Dec 29, 2010ABRXYesYes► Subscribe► Subscribe ► Subscribe
Endo Pharms
OPANA ER
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL201655-004Dec 9, 2011DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Endo Pharms
OPANA ER
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL201655-002Dec 9, 2011DISCNYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Endo Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo Pharms
FROVA
frovatriptan succinate
TABLET;ORAL021006-001Nov 8, 2001► Subscribe► Subscribe
Endo Pharms
OPANA ER
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL021610-004Jun 22, 2006► Subscribe► Subscribe
Endo Pharms
OPANA ER
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL021610-006Feb 29, 2008► Subscribe► Subscribe
Endo Pharms
OPANA ER
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL021610-003Jun 22, 2006► Subscribe► Subscribe
Endo Pharms
MOBAN
molindone hydrochloride
TABLET;ORAL017111-008Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Endo Pharms
OPANA ER
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL021610-002Jun 22, 2006► Subscribe► Subscribe
Endo Pharms
OPANA ER
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL021610-004Jun 22, 2006► Subscribe► Subscribe
Endo Pharm
VANTAS
histrelin acetate
IMPLANT;SUBCUTANEOUS021732-001Oct 12, 2004► Subscribe► Subscribe
Endo Pharms
OPANA ER
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL021610-006Feb 29, 2008► Subscribe► Subscribe
Endo Pharm
SUPPRELIN LA
histrelin acetate
IMPLANT;SUBCUTANEOUS022058-001May 3, 2007► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ENDO PHARM drugs

Drugname Dosage Strength Tradename Submissiondate
cyanocobalamin
Nasal Spray500 mcg/spray
NASCOBAL
4/28/2017
testosterone undecanoate
Injection250 mg/mL
AVEED
6/11/2014
testosterone
Gel10 mg/actuation
FORTESTA
8/14/2012
frovatriptan succinate
Tablets2.5 mg
FROVA
3/9/2011
oxymorphone hydrochloride
Extended-release Tablets30 mg
OPANA ER
6/12/2008
oxymorphone hydrochloride
Extended-release Tablets7.5 mg and 15 mg
OPANA ER
5/29/2008
oxymorphone hydrochloride
Extended-release Tablets5 mg, 10 mg, 20 mg and 40 mg
OPANA ER
11/23/2007

Non-Orange Book Patents for Endo Pharm

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,969,529 Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers► Subscribe
8,323,641Nanoparticulate compositions having lysozyme as a surface stabilizer► Subscribe
8,114,384Process for the production of an abuse-proofed solid dosage form► Subscribe
7,998,507Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors► Subscribe
7,157,097Penetration enhancing and irritation reducing systems► Subscribe
8,309,136In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions► Subscribe
6,375,986 Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate► Subscribe
7,850,995Bioadhesive nanoparticulate compositions having cationic surface stabilizers► Subscribe
7,276,249Nanoparticulate fibrate formulations► Subscribe
8,652,464Method of treatment using nanoparticulate compositions having lysozyme as a surface stabilizer► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Endo Pharm Drugs

Country Document Number Estimated Expiration
EcuadorSP066346► Subscribe
World Intellectual Property Organization (WIPO)0126635► Subscribe
Japan4460827► Subscribe
World Intellectual Property Organization (WIPO)2006009801► Subscribe
Japan4680891► Subscribe
Denmark1699440► Subscribe
Poland208484► Subscribe
Japan4939218► Subscribe
World Intellectual Property Organization (WIPO)2005063214► Subscribe
European Patent Office1404331► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Endo Pharm Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
02/028Ireland► SubscribePRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013
00071Netherlands► SubscribePRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920
00103Netherlands► SubscribePRODUCT NAME: FROVATRIPTAN EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 27211RVG 27212 2002190419; FIRST REGISTRATION: NL 24548 20001212
C0019France► SubscribePRODUCT NAME: FROVATRIPTAN SUCCINATE MONOHYDRATE; NAT. REGISTRATION NO/DATE: NL 24548 20001212; FIRST REGISTRATION: FR - NL 24548 20001212
C0003France► SubscribePRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920
C/GB02/027United Kingdom► SubscribePRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425
C/GB03/014United Kingdom► SubscribePRODUCT NAME: 3 METHYLAMINO-6-CARBOXAMIDO-1, 2, 3, 4-TETRAHYDROCARBAZOLE ("FROVATRIPTAN") INCLUDING A SALT, SOLVATE OR HYDRATE THEREOF; REGISTERED: FR NL 24548 20001212; UK PL 16239/0017 20021007; UK PL 16239/0018 20021007
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Fuji
Healthtrust
Citi
Covington
Express Scripts
Argus Health
Merck
Fish and Richardson
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot